novel treatment strategy
metastatic cancer
bi-modal treatment strategy
novel bi-modal curative treatment strategy
limited metastatic NSCLC
limited metastatic lung cancer IMMUNOSABR
Palliative treatment
concept of limited metastatic disease
Clinical proof of concept
patients
irradiated metastatic site
clinical efficacy
clinical implementation
ambitious personalised biomarker strategy
powerful synergistic anti-tumour strategy
tumour tissue
study
curative intent
tumour-specific immunocytokine L19-IL2
small cell lung cancer
direct cytotoxic effect of SABR
multicentre randomised phase
abscopal effect of radiation
High precision stereotactic ablative radiotherapy
combination of immunotherapy
development of L19
strong biomarker work packages
state-of-the-art immunological monitoring approaches
promising non-invasive imaging techniques
distance
current standard of care
NCT02735850
commercial drug
blood
evidence
animation
new paradigm
sites
actionable mutation
oligo